Switch Therapeutics Raises $52M to Advance First-of-its-Kind RNAi Technology


Switch Therapeutics

Switch Therapeutics has announced its launch after raising $52 million in financing, with its Series A round being co-led by Insight Partners and UCB Ventures. Other investors that contributed to the round included existing investors Upfront Ventures and BOLD Capital Partners, as well as new investors Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, and PhiFund Ventures.

The preclinical stage biotech company is pioneering a new way of using RNA science to treat diseases, with a focus on a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.

The company plans to use the funds to select and advance a development candidate for its lead program for the treatment of a central nervous system disease and recruit top R&D and corporate talent to help accelerate its growth. It will also explore opportunities to expand its CASi platform into new areas through potential pharmaceutical collaborations.

Related Stories